All about Servier
2022-2023 INTEGRATED ANNUAL REPORT
Committed to therapeutic progress to serve patient needs
Founded to serve health, our Group aspires to make a meaningful social impact for patients and for a sustainable world. Our vocation: Committed to therapeutic progress to serve patient needs.
all about servier
Our model for value creation
Our model for value creation highlights how Servier generates tangible and intangible advantages for all of its stakeholders, integrating sustainability and financial performance with a holistic approach.
all about servier
Our governance model
Governed by a Foundation and free from shareholder pressure, Servier can fully focus on its vocation as a Group committed to therapeutic progress to serve patient needs.
all about servier
Our presence throughout the world
Our medicines are available in over 150 countries. Pursuing our vocation, we bolster our presence in regions where patient needs are greatest.
150
Over 150 countries where the Group’s medicines are distributed
16
production sites
4
research centers and 3 hubs with 15 clinical development centers
all about servier
High-performing R&D to serve patient needs
Our ambition is clear: to strengthen our leadership position in select therapeutic areas, especially cancers and rare diseases.
To achieve this, our teams are focusing their research efforts, leveraging open innovation and AI.
all about servier
Our ambition for 2030
Our 2030 strategy fulfils our vocation and takes account of the health challenges facing society today and into the future. We are driven to achieve our ambition as cancer is ever-more prevalent and cardiometabolic diseases still represent a major cause of death around the world.
all about servier
Making a meaningful social impact for patients and a sustainable world
The notion of corporate social responsibility (CSR) permeates every area of our corporate strategy. It is at the heart of our Servier 2030 ambition.
